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Giant cell arteritis (GCA) is the most common form of vasculitis in individuals older than 50 years in Western countries. To shed light
onto the genetic background influencing susceptibility for GCA, we performed a genome-wide association screening in a well-powered
study cohort. After imputation, 1,844,133 genetic variants were analyzed in 2,134 case subjects and 9,125 unaffected individuals from
ten independent populations of European ancestry. Our data confirmed HLA class II as the strongest associated region (independent sig-
nals: rs9268905, p ¼ 1.94 3 1054, per-allele OR ¼ 1.79; and rs9275592, p ¼ 1.14 3 1040, OR ¼ 2.08). Additionally, PLG and P4HA2
were identified as GCA risk genes at the genome-wide level of significance (rs4252134, p ¼ 1.23 3 1010, OR ¼ 1.28; and rs128738,
p ¼ 4.60 3 109, OR ¼ 1.32, respectively). Interestingly, we observed that the association peaks overlapped with different regulatory
elements related to cell types and tissues involved in the pathophysiology of GCA. PLG and P4HA2 are involved in vascular remodelling
and angiogenesis, suggesting a high relevance of these processes for the pathogenic mechanisms underlying this type of vasculitis.Introduction
During the last decade, genome-wide association studies
(GWASs), in which common genetic variation across the
whole genome is interrogated in a hypothesis-free fashion,
were a breakthrough in biomedical research methodology
and have led to the identification of thousands of robust
genetic associations within a wide spectrum of complex
human diseases.1 However, some diseases of low preva-1Instituto de Parasitologı́a y Biomedicina ‘‘López-Neyra,’’ CSIC, PTS Granad
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 2017 American Society of Human Genetics.lence have received less attention due to the difficulty in
recruiting well-powered study cohorts, even though rare
diseases result in a significant disease burden. An example
is giant cell arteritis (GCA [MIM: 187360]), the most com-
mon form of vasculitis in Western countries in people over
50 years old. GCA is characterized by chronic inflamma-
tion of large arteries, such as the aorta and the carotid
arteries and its extracranial branches, which may lead to
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Miguel A. González-Gay,46 and Javier Martı́n1vision loss, scalp and tongue necrosis, aortic dissection/
rupture, and cerebral infarction.2–4 Although the genetic
component of GCA has previously been investigated
following a candidate gene approach,most of the described
genetic associations were based on underpowered analyses
and usually failed to be replicated in independent popula-
tions.5
Recently, an international collaborative effort involving
European and North American research consortia has
made possible more powerful studies, including an Immu-
nochip study, that have identified firm risk signals for
GCA predisposition, such as HLA molecules and key genes
of the immune response like protein tyrosine phosphatase,
non-receptor type 22 (PTPN22 [MIM: 600716]), and inter-
leukin 17A (IL17A [MIM: 603149]).6–8 Taking advantage of
the large sample collection that this collaboration has
enabled, comprising ten independent populations of Euro-
pean ancestry that cover the whole gradient for prevalence
of the disease, we performed an agnostic genetic study in
GCA at the genome-wide level.Subjects and Methods
Study Population
This study included a total of 2,134 GCA-affected case subjects
and 9,125 unaffected control subjects from ten independent
populations of European ancestry: Spain (805 case and 1,323
control subjects), UK (352 case and 2,965 control subjects), Italy
(271 case and 960 control subjects), North America (176 case
and 1,181 control subjects from USA and Canada), Germany
(160 case and 667 control subjects), France (114 case and 488
control subjects), Norway (104 case and 121 control subjects),
the Netherlands (69 case and 638 control subjects), Switzerland
(46 case and 500 control subjects), and Ireland (37 case and
282 control subjects). The diagnosis of GCA was established ac-
cording to the 1990 American College of Rheumatology classifi-
cation criteria for this disease.9 In addition, the diagnosis wasOslo 0424, Norway; 32Department of Rheumatology, Hospital of Southern N
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The Amsubsequently confirmed by either a biopsy of the temporal artery
(89.83%) or arterial imaging (10.17%) consistent with GCA.
A detailed description of the main clinical characteristics of the
different case cohorts is provided in Table S1. All participants
signed an informed consent form before being enrolled in the
study. The procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) of all participant
centers.
Genotyping and Quality Controls
Genomic DNA from peripheral blood samples of all GCA-af-
fected case subjects as well as the Spanish and Irish control
subjects were screened using the GWAS platform ‘‘Infinium
HumanCore Beadchip’’ in an iScan System and the Genotyping
Module (v.1.9) of the GenomeStudio software (Illumina).
The genotyping was conducted in the Genomics and Geno-
typing Unit of the Pfizer-University of Granada-Junta de Anda-
lucı́a Centre for Genomics and Oncological Research (GENYO,
Granada, Spain), according to the manufacturer’s protocol.
SNPs with a cluster separation < 0.4 were removed after the
calling.
Genotyping data from the remaining control population were
obtained from nine cohorts of geographically matched European
ancestries included in previous studies10–17 (Table S2).
All studies were subjected to stringent quality-control measures
separately based on the same analytical protocol using PLINK
v.1.07.18 Specifically, we filtered out SNPs with call rates < 0.98
andminor allele frequencies (MAF)< 0.01 and those that deviated
from Hardy-Weinberg equilibrium (HWE; p < 0.001 in both case
and control subjects). Similarly, samples with less than 95% of suc-
cessfully called SNPs, and one subject per pair of first-degree rela-
tives (identity by descent > 0.4) were removed. Sex chromosomes
were also excluded from the analysis.
Finally, to check the consistency of the results, we re-genotyped
the Spanish samples for the associated signals using predesigned
TaqMan 50 SNP genotyping assays (assay IDs: C__16222465_10,
C__25614474_20, and C___2397211_10) in a 7900HT Fast Real-
Time PCR System (Applied Biosystems) and compared the TaqMan
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Imputation Methods
After applying the QC filters, whole-genome SNP genotype
imputation was carried out with IMPUTE v.219 using the com-
bined 1000 Genome Project Phase III (1KGPh3) data as reference
panel, which includes 2,504 individuals.20 In brief, for each in-
dividual dataset, the strand orientation, chromosome position,
and SNP identification were updated in PLINK to match build
37 (hg19) of the 1KGPh3. Next, PLINK-formatted files were con-
verted to the appropriate format with GTOOL and the geno-
typing data were split into chunks of 50,000 Mb covering
whole-genome regions. Imputation was done separately for
each study. To ensure quality of imputed SNPs, the most likely
call was used for merging genotypes, but only if the most likely
call exceeded a probability threshold of 0.9 (the genotype was
set to missing otherwise). As the individual imputation of each
case/control set could lead to stratification, imputed data were
also subjected to rigorous quality filters in PLINK, including
removal of SNPs with call rates < 0.98, MAFs < 0.01, and those
that were not in HWE (p < 0.001). Moreover, after merging
case/control sets, singleton SNPs and those showing strong evi-
dence of discordance in the genotype distribution between
cases and controls due to possible miscalling were removed us-
ing an in-house Perl script. Finally, principal component (PC)
analyses were conducted to control for possible population strat-
ification using PLINK and the GCTA64 and R-base software un-
der GNU Public license v.2. For that, we calculated and plotted
the ten first PCs of each individual and those samples located
at >4 standard deviations from the cluster centroids of each
cohort were considered outliers and, consequently, excluded
from the analyses.
The final numbers of individuals and SNPs that remained in the
filtered datasets are shown in Table S2.Statistical Analyses
Table S3 shows the estimation of the overall statistical power of
this study accordingly with the CaTS Power Calculator for Genetic
Studies software, which implements the methods described in
Skol et al. assuming an additive genetic model.21
PLINK was used to conduct all the case/control analyses.
First, the genotype frequencies of all markers were compared be-
tween case and control subjects of every individual dataset by lo-
gistic regression on the best-guess genotypes (>0.9 probability)
assuming an additive model and using the ten first study-specific
PCs and the gender as covariates. Next, a combined analysis of
all studies was performed using the inverse variance weighted
meta-analysis under a fixed effects model. In order to maximize
the total number of SNPs analyzed without compromising the
consistency of the results, we tested all SNPs present in the largest
GCA sample set (Spain) and in one or more additional studies
(i.e., ranging from 2 to 10 studies but including always the Spanish
set). A total of 1,844,133 were evaluated in the meta-analysis. To
identify independent effects across associated regions, depen-
dency analyses at the cohort level genome-wide scans were con-
ducted in PLINK by stepwise logistic regression with adjustment
for the most associated signals in the common set of SNPs, fol-
lowed by inverse variance weightedmeta-analysis under a fixed ef-
fects model. The heterogeneity of the odds ratios (OR) across the
different studies was estimated using both I2 and Cochran’s
Q tests. The Manhattan plots were obtained with an in-house
R script, and the zooms of the associated regions were obtained
with LocusZoom v.1.1.2266 The American Journal of Human Genetics 100, 64–74, January 5, 2Functional Annotation of Associated Variants
We evaluated the putative functional implications of the GCA risk
loci by implementing our data with publicly available functional
annotation data.
Despite the high efficiency of the imputation process, it was not
possible to obtain imputed types for every known polymorphism.
Therefore, in a first step, we identified all the SNP taggers (r2 > 0.8)
of the associated signals of our GWAS using the 1KGPh3 data for
the European populations and PLINK. All taggers were considered
equally as candidates for prioritizing casualty or hypothesizing
possible molecular causes of the observed associations in the sub-
sequent bioinformatic approaches. Then, we explored whether
the taggers of each GWAS signal had possible functional implica-
tions. The tools PolyPhen-223 and Combined Annotation Depen-
dent Depletion (CADD)24 were used to evaluate possible damaging
effects on the protein sequence of coding non-synonymous
SNPs. Regarding the intronic and intergenic variants, we explored
whether they lay within known or predicted regulatory DNA ele-
ments (including regions of DNAase hypersensitivity, binding
sites of transcription factors, promoter regions, chromatin marks,
etc.) and whether they had predictive effects on clinical pheno-
types using the online tools for exploring annotations of the
noncoding genome RegulomeDB25 and HaploReg v.4.1.26 Sources
of these databases include public datasets from the projects Gene
Expression Omnibus (GEO), the Roadmap Epigenomics, the Ency-
clopedia of DNA Elements (ENCODE), and 1KGPh3, as well as
published literature.
In addition, to provide an illustrative picture of the current
knowledge on the GCA genetics, we conducted a molecular
pathway enrichment analysis, considering both previously sug-
gested GCA genes and those showing an association with disease
susceptibility in this study, using the tool for that purpose of the
Gene Ontology (GO) reference genome project,27,28 powered by
the Protein Analysis Through Evolutionary Relationships
(PANTHER) Classification System.29 Biological pathways showing
p values lower than 0.05 after Bonferroni correction were consid-
ered associatedwith the disease. Finally, predictive protein-protein
relationships among these same genes were also tested using the
Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) database.30 Only candidate genes that showed statisti-
cally significant signals after correction for multiple testing
(which was performed with a previously validated method to con-
trol the genome-wide type 1 error rate at 0.0531) were included in
the above analyses.Results
Testing for Association with Disease Susceptibility
Three genomic regions contained association signals at the
genome-wide level of significance in the overall meta-anal-
ysis: human leukocyte antigen (HLA) class II, plasminogen
(PLG [MIM: 173350]), and prolyl 4-hydroxylase subunit
alpha 2 (P4HA2 [MIM: 600608]) (Tables 1 and S4; Figure 1).
Within the HLA region, the top hit was rs9268905
(p ¼ 1.94 3 1054, OR ¼ 1.79, 95% CI 1.67–1.93), located
between HLA-DRA (MIM: 142860) and HLA-DRB1 (MIM:
142857). Dependence analyses suggested a possible inde-
pendent effect on disease susceptibility within the HLA-
DQA1 (MIM: 146880)/HLA-DQA2 (MIM: 613503) genomic










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The AmSNP ¼ rs9275592, adjusted p ¼ 1.78 3 1010, OR ¼ 1.48,
95% CI 1.31–1.66). No association at the genome-wide
level of significance remained within the HLA after condi-
tioning on both rs9268905 and rs9275592 (Table S5 and
Figure S1).
Outside the HLA region, rs4252134, located in an intron
of PLG at chromosome 6, represented the most strongly
associated variant (p ¼ 1.23 3 1010, OR ¼ 1.28, 95% CI
1.19–1.39, Figure 2). Although some heterogeneity was
observed between studies (I2 ¼ 48.8), consistent OR direc-
tions of the minor allele (toward risk) were observed in all
sets (Tables 1 and S4; Figure S2). Other SNPs within the
gene (both intronic and exonic) also showed significant
p values, but their statistical significance was lost when
conditioned on rs4252134 (Table S6 and Figure S3). Finally,
another intronic SNPofP4HA2at chromosome5, rs128738,
surpassed the statistical threshold (p ¼ 4.60 3 109,
OR ¼ 1.32, 95% CI 1.20–1.45). This genomic region also
showed additional suggestive signals, but none of them
was significant at the genome-wide level (Figure 2).
To confirm the above results, we obtained direct
genotypes of the whole Spanish cohort using TaqMan
probes for rs128738 and two perfect proxies (r2 ¼ 1) of
rs4252134 and rs9268905 (rs4252125 and rs2395185,
respectively). The overall concordance reached after com-
paring TaqMan types with the corresponding imputed
data was 99.94% for rs128738, 99.81% for rs4252134/
rs4252125, and 99.94% for rs9268905/rs2395185.
Functional Annotations of Proxies of the Non-HLA
Hits
To prioritize variants that could drive the observed non-
HLA associations, we identified all the SNPs in high link-
age disequilibrium (LD, r2 > 0.8) with the lead signals in
the European populations of 1KGPh3 (Tables S7 and S8)
and used public online annotation tools to evaluate their
possible functional implications. One PLG polymor-
phism (rs4252125) was annotated as missense in the
dbSNP database. However, this variant was predicted to
be benign according to PolyPhen-2 and showed no evi-
dence of being potentially pathogenic after scoring the
deleteriousness with CADD (raw score ¼ 0.63, PHRED-
like scaled C-score ¼ 0.104). Then, using RegulomeDB,
we identified those SNPs overlapping with known and
predicted DNA elements with a higher probability of reg-
ulatory effects (score % 3) (Tables S7 and S8) and per-
formed a detailed functional annotation of these tagger
variants and the lead SNPs using HaploReg (Tables 2
and S9–S11). Most of them overlapped with DNase hy-
persensitivity sites and histone marks enriched at pro-
moters and enhancers (Table 2). Interestingly, some of
these annotations were related to cell types and tissues
involved in GCA pathophysiology. For example, PLG
rs4252135 co-localized with DNase peaks in different
immune cell lines and had a predicted enhancer
chromatin state in lymphoblastoid cells (Tables S9 and
S10). A higher enrichment of promoter and enhancererican Journal of Human Genetics 100, 64–74, January 5, 2017 67
Figure 1. Manhattan Plot Representation of the GWAS Results
The log10 of the inverse variance-weighted meta-analysis p values are plotted against their physical chromosomal position. The red
line represents the genome-wide level of significance (p < 5 3 108). The most relevant associations are highlighted.epigenetic marks in these tissues was observed for the
prioritized P4HA2 variants (Table S9). Specifically, the
lead signal rs128738 overlapped with enhancer histone
marks in immune cells and with the imputed Transcrip-
tion 30 Enhancer mark in the aorta (Table S10). Addition-
ally, P4HA2 rs156023 showed evidence of influencing
enhancer activity in hematopoietic stem cells and neu-
trophils as well as promoter activity in mononuclear cells
and monocytes (Tables S9 and S10).
In addition, key regulatory proteins (some of them
related to the immune response) bound by ChIP-seq exper-
iments as well as relevant motif disruptions were reported
in most cases (Table 2).
Consequently, most prioritized SNPs also correlated with
eQTL effects in peripheral blood monocytes and lympho-
blastoid cells (Tables 2 and S11). Interestingly, rs101194
and rs152054 were reported to affect P4HA2 expression
in arterial tissues in the Genotype-Tissue Expression
(GTEx) study,32 with rs101194 specifically acting as cis-
eQTL in the aorta (Table S11).Candidate Genes and Pathway Analysis
We also checked the statistical significance in our GWAS
of previously described GCA-associated genomic re-
gions (5100 kbp 30 and 50 of the reported gene) through
candidate gene and Immunochip studies.5,8 Significant
associations after controlling for multiple testing were
observed across most of the analyzed regions, with
the myeloperoxidase (MPO [MIM: 606989]), tumor
necrosis factor (TNF [MIM: 191160]), interleukin 6 (IL6
[MIM: 147620]), nitric oxide synthase 2 (NOS2 [MIM:
163730]), and PTPN22 regions harboring the strongest
non-HLA hits (MPO rs10853005, p ¼ 7.19 3 105,
OR ¼ 0.84; TNF rs4959077, p ¼ 2.08 3 104, OR ¼
1.42; IL6 rs77741999, p ¼ 2.17 3 104, OR ¼ 1.20;
NOS2 rs4255826, p ¼ 5.75 3 104, OR ¼ 0.87; and
PTPN22 rs2476601, p ¼ 7.88 3 104, OR ¼ 1.24) (Tables68 The American Journal of Human Genetics 100, 64–74, January 5, 2S12 and S13). Subsequently, we accomplished a protein-
protein interaction (PPI) and biological pathway enrich-
ment analysis with those candidate hits showing statisti-
cally significant signals after correction for multiple
testing in our GWAS (Table S13). The molecular network
of the selected proteins had significantly more interac-
tions than expected (number of nodes, 13; number of
edges, 14; average node degree, 2.15; clustering coeffi-
cient, 0.851; expected number of edges, 3; PPI enrich-
ment, p ¼ 1.13 3 106; Figure 3). Interestingly, PLG
represented a relevant node showing evidence of inter-
action with different proteins (e.g., NOS3, IL-6, and
TNF) (Figure 3). Regarding the functional enrichments
of the network, the most significantly associated GO
processes were those related to regulation of both cell-
cell adhesion and the immune/inflammatory response
(Table S14).Discussion
This study represents an unbiased screening of genetic
variation in GCA at the genome-wide level. GCA was one
of the few types of vasculitis in which GWAS data were
not available. Therefore, the results presented here may
help to better understand the pathogenic mechanisms un-
derlying this condition and its genetic similarities with
other vasculitides. In this sense, our data reinforce the
idea of GCA as an archetypal HLA class II disease mediated
by an antigen-driven immune response,33 which is in
contrast not only to Takayasu’s arteritis (TAK [MIM:
207600]), another large-vessel vasculitis, but also to other
forms of vasculitis associated with class I molecules like
Behçet disease (MIM: 109650).34
Two independent association signals with GCA predis-
position were observed within the HLA region, one located
between HLA-DRA and HLA-DRB1 and another one be-
tween HLA-DQA1 and HLA-DQA2. This is consistent with017
Figure 2. Regional Plots of the Associ-
ated Loci with GCA outside the HLA
Region in the Overall Meta-analysis
(A) Plasminogen (PLG) region.
(B) Prolyl 4-hydroxylase subunit alpha
2 (P4HA2) region.
Lead variants are highlighted in violet.the amino acid model that we proposed using imputed Im-
munochip data to explain the HLA class II association with
GCA, which comprised the positions 13 and 56 of the
DRb1 and DQa1 molecules, respectively.8 Indeed, the
strongest hit in the Immunochip study (which had partial
overlap of the sample collections with this one) was a SNP
that tagged the model (rs477515) in high LD with the two
independent HLA lead SNPs that we observed in our GWAS
(rs9268923: r2 ¼ 0.84, D’ ¼ 0.95; rs3957146: r2 ¼ 0.23,
D’ ¼ 0.99).
Regarding the non-HLA associations, several variants
within PLG were firmly associated with risk to develop
GCA at the genome-wide level of significance in this study,
although they all were in high LD and represented a singleThe American Journal of Humansignal according to the dependence
analysis. This gene encodes a secreted
blood zymogen that can be converted
through a complex conformational
modification into two different active
proteins, plasmin and angiostatin.35
The plasminogen system has an
important role in a wide spectrum of
physiological processes, including
wound healing, fibrinolysis, angio-
genesis, and lymphocyte recruitment
and inflammation via production of
cytokines and reactive oxygen spe-
cies,36,37 all of them relevant pro-
cesses in GCA.38 Considering the
opposite roles of plasmin and angios-
tatin in the induction of pro-angio-
genic processes,36,37 we hypothesize
that the PLG risk alleles could unbal-
ance the metabolism of its encoded
protein leading to the characteristic
pro-inflammatory phenotypes of
GCA, although there is a lack of
experimental support for this
assumption. Interestingly, anti-plas-
minogen antibodies have been corre-
lated with systemic disease activity
in ANCA-associated vasculitis (MIM:
608710),39 a type of vasculitis in-
volving small- to medium-sized blood
vessels that is also strongly associated
with HLA class II molecules.40 In
addition, PLG has been shown to be
a shared risk gene for coronary arterydisease (MIM: 608320) and periodontitis (MIM: 260950),
characterized by chronic inflammation,41 and multiple
sclerosis (MIM: 126200), which is also an immune-medi-
ated condition.42 Future studies aimed at improving the
understanding of the zymogen activation may shed light
into the PLG association with GCA.
P4HA2 represents the second non-HLA hit in our
GWAS. This gene encodes an isoform of the alpha
subunit of the collagen prolyl 4-hydroxylase, which cat-
alyzes the formation of 4-hydroxyproline from proline
residues that is essential for collagen biosynthesis, as it
is required for the proper three-dimensional folding of
newly synthesized procollagen chains.43 P4HA2 is con-
sidered an important hypoxia response gene and itsGenetics 100, 64–74, January 5, 2017 69
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(PWM) GRASP QTL Traits p Value
Ref
(PMID) eQTL Hits
rs4252134 6:161153527 PLG (intronic) 0 NA 6 – – – – – gene expression of
DDR1 in peripheral
blood monocytes
3.31 3 106 20502693 –
rs4252126 6:161152294 PLG (intronic) 1,233 0.995 1f yes – yes CTCF Pax-6 – – – –




COMP1 gene expression of
DDR1 in peripheral
blood monocytes
2.92 3 106 20502693 –
rs34126283 6:161130002 PLG (intronic) 23,525 0.920 3a yes yes yes GATA2 Cdc5, E2F, Evi-1,
HDAC2, PLZF,
Pou2f2, TATA
– – – –
rs4252125 6:161152240 PLG
(missense)
1,287 0.995 3a yes – yes CTCF, RAD21 AP-3 gene expression of
UNQ9391 in liver
4.09 3 1014 22006096 –
rs128738 5:131540875 P4HA2
(intronic)
0 NA ND yes yes* – – BDP1 – – – 24
rs101194 5:131515413 P4HA2
(intergenic)









1.16 3 108 20502693 –
rs152054 5:131519540 P4HA2
(intergenic)







– – – 25
rs152051 5:131539025 P4HA2
(intronic)







4.66 3 109 17873874 28
rs156023 5:131545168 P4HA2
(intronic)
4,293 0.967 3a yes* yes* – – AIRE, LBP-1,
LBP-9
– – – 22
Chromatin marks in blood tissues are indicated with an asterisk. Abbreviations are as follows: SNP, single nucleotide polymorphism; GRCh37, genome reference consortium human genome build 37; bp, base pair; RDB,
Regulome database; PWM, position weight matrix ID; GRASP, genome-wide repository of associations between SNPs and phenotypes; PMID, PubMed identifier; eQTL, expression quantitative trait loci. RDB scores: 1f,

















































Figure 3. Interaction Network Formed
for GCA Risk Loci
GWAS genes of this study and those
previously identified through Immuno-
chip and consistent candidate gene
studies were included in the analysis.
STRING database was used to look for
both direct and indirect interactions
among selected genes. The width of the
blue lines indicates the reliability of each
interaction.expression is regulated by hypoxia-inducible factor-1
(HIF-1).44 Other relevant HIF-1-induced genes include
serpin family E member 1 (SERPINE1 [MIM: 173360],
which is the principal inhibitor of the plasmin activa-
tion) and genes that have been previously associated
with GCA risk through candidate gene studies, such as
vascular endothelial growth factor A (VEGFA [MIM:
192240], a potent endothelial growth factor), matrix
metalloproteinase 9 (MMP9 [MIM: 120361], involved in
the breakdown of extracellular matrix), and IL6 (a pro-in-
flammatory cytokine).5,45,46 Indeed, the hypoxic induc-
tion of all these HIF-1 target genes (and, indirectly, the
inhibition of plasmin formation) is also related to the
typical processes involved in the lesions of GCA-affected
individuals, i.e., fibrosis, inflammation, destruction of
the internal elastic lamina, and vascular remodeling,
with proliferation and migration of medial myofibro-
blasts and neoangiogenesis.38,45 The prioritized P4HA2
SNPs proposed here correlated with cis-eQTLs in immune
cells and arterial tissues. In particular, expression data
indicate that rs101194 may influence P4HA2 expression
in whole blood, lymphoblastoid cells, and the aorta,
which is one of the most severely affected vessels in
GCA.32,38,47–49
Overall, our results are consistent with the currently
accepted understanding of the pathophysiology of GCA,
in which vascular remodeling and angiogenesis, either
under hypoxic conditions or by dysregulation of hy-
poxia-sensitive genes, are critical to the development
of the clinical presentations.50 Future analysis of the ge-
netic overlap between GCA and other forms of vasculitisThe American Journal of Humanusing GWAS data may help to eluci-
date whether these pathogenic
processes are a common feature in
vasculitides and to identify other
relevant pathways for the develop-
ment of GCA.
To summarize, through the analysis
of common variation across the
whole genome, we have identified
PLG and P4HA2 as the main non-
HLA genetic factors underlying
GCA predisposition. Their crucial
role in neoangiogenesis highlights
the high relevance of this process inthe pathogenic mechanisms leading to this form of
vasculitis.
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